Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the of Surgeons Oncology Group. Novartis supplied Gleevec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Gleevec.

Gleevec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit- positive GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Gleevec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... voice on the recording was low and calm as the speaker ... with the human immunodeficiency virus (HIV) that causes AIDS: “My heart ... I was on the floor flat on my face boohooing, crying ... recording ended less than 10 minutes later. “Don’t feel like this ... is just God setting you up for something greater,” the anonymous ...
(Date:7/23/2014)... By Kathleen Doheny ... (HealthDay News) -- Weight-loss surgery appears to have an ... symptoms in women, according to a new study. ... a weight-loss surgery program reported having incontinence prior to ... their urinary symptoms either improved or disappeared, said study ...
(Date:7/23/2014)... By Amy Norton ... -- The timing of a girl,s first menstrual period may ... a new study suggests. Researchers have identified over ... of menarche -- a woman,s first menstrual period. The researchers ... a number of diseases ranging from type 2 diabetes to ...
(Date:7/23/2014)... genes have been focused on the regions of the ... the form of amino acids thus proteins. But just ... activator which controls the expression and activity of the ... the role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, ...
(Date:7/23/2014)... likelihood of forming false memories, according to research published ... Association for Psychological Science. , In a study conducted ... of California, Irvine and colleagues, sleep-deprived people who viewed ... false information about the photos were more likely to ... were those who got a full night,s sleep. , ...
Breaking Medicine News(10 mins):Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Sleep deprivation may increase susceptibility to false memories 2
... Hospitals that have better working conditions for nurses are ... to a recent report , led by researchers ... are the number six cause of death in the ... workforce in the nation's hospitals, are in a unique ...
... claimed to have developed super-oxidised water, which speeds up ... is made by passing it through a salt membrane ... fungi. ,The company claims that the solution ... ,We would welcome any safe effective treatment which could ...
... has found how medical science could employ aspirin and ... in certain high-risk individuals. ,The study ... Sanford Markowitz at the Ireland Cancer Center. ... mechanism by which the use of aspirin and nonsteroidal ...
... Army hospital here has conducted an accident victim's multiple organ ... to three individuals. ,The retrievals were conducted ... and the organs were transplanted Thursday on two patients at ... ,Donor Ramesh Chand, 60, whose two sons serve ...
... their birth, healthy babies will look you in the eye. ... 9 months, they will exchange smiles. If they ... to worry. ,There is a growing field ... increasingly looking for early signs in babies of autism, attention ...
... Chinese exporters. After the furore over pet food, it is ... under the scanner. ,The federal government has announced ... Food and Drug Administration decides whether the product contains diethylene ... fluid. ,The imports will be released only if ...
Cached Medicine News:Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 2Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 3Health News:Aspirin may Help to Prevent Colon Cancer in High-risk Individuals 2Health News:Army Hospital Conducts First Multiple Organ Retrieval and Transplantation 2Health News:Watch Out for Signs of Autism in Babies! 2Health News:Watch Out for Signs of Autism in Babies! 3Health News:US Halts Import of Chinese Toothpaste 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: